Pharmacokinetics of an immediate-release oral formulation of Fampridine (4-aminopyridine) in normal subjects and patients with spinal cord injury.
about
The therapeutic mode of action of 4-aminopyridine in cerebellar ataxia.Sustained-release fampridine for symptomatic treatment of multiple sclerosis.Dalfampridine sustained-release for symptomatic improvement of walking speed in patients with multiple sclerosis.A randomized trial of 4-aminopyridine in EA2 and related familial episodic ataxiasExtended-release dalfampridine in the management of multiple-sclerosis-related walking impairment.Fampridine-SR for multiple sclerosis and spinal cord injury.Sustained-release fampridine for multiple sclerosis.Management options in multiple sclerosis-associated fatigue.4-aminopyridine toxicity: a case report and review of the literature.Enhancing neural transmission in multiple sclerosis (4-aminopyridine therapy).Development of dalfampridine, a novel pharmacologic approach for treating walking impairment in multiple sclerosis.A phase 3 trial of extended release oral dalfampridine in multiple sclerosis.Aminopyridines for the treatment of neurologic disorders.Assessment of the cardiac safety of fampridine-SR sustained-release tablets in a thorough QT/QTc evaluation at therapeutic and supratherapeutic doses in healthy individuals.Effects of 4-Aminopyridine on Cloned hERG Channels Expressed in Mammalian Cells.Single-Dose pharmacokinetics of sustained-release fampridine (Fampridine-SR) in healthy volunteers and adults with renal impairment.Dalfampridine in patients with downbeat nystagmus--an observational study.Potassium channel blocker 4-aminopyridine is effective in interictal cerebellar symptoms in episodic ataxia type 2--a video case report.Randomized, Placebo-controlled Crossover Study of Dalfampridine Extended-release in Transverse Myelitis.Suppression of Inflammatory Demyelinaton and Axon Degeneration through Inhibiting Kv3 Channels.Phase 2 trial of sustained-release fampridine in chronic spinal cord injury.Parallel evaluation of two potassium channel blockers in restoring conduction in mechanical spinal cord injury in rat.Contrasting effects of cord injury on intravenous and oral pharmacokinetics of diclofenac: a drug with intermediate hepatic extraction.Reported direct aminopyridine effects on voltage-gated calcium channels is a high-dose pharmacological off-target effect of no clinical relevance
P2860
Q30495678-F4CC3BD8-37A2-46A4-9E44-83803E19781AQ34013705-FF82A96C-AB7B-4059-A4C7-9CF34FE0BC6FQ34729016-EE740A81-045D-4A2B-AD92-4A898AE66CF2Q35104451-3088C021-69D2-41D9-A0D6-20FFCD965414Q36072693-AECAF240-F811-4B42-A955-B6143D22129EQ36817031-933C7A41-AF3A-440B-9423-D2A2CBADFD7FQ37528447-04C8409A-752A-48EA-9E5B-53FC5DF947C0Q37973392-0D4F079B-F192-4C6C-A474-AC55B320CE06Q38025327-AD24E289-3F1E-4771-B843-D13387A12EB6Q38062861-F91A6577-0E39-4BB5-84FC-C0CCE1FE425FQ38243024-62F6BC96-891A-4FB5-A282-CA8FD275B9D7Q38480300-6B097735-DB30-40D7-BD45-DC78B309A4FFQ39153784-1C23BC04-72E7-4D0F-92FA-F63C400B0187Q39909171-D437FF7A-3935-4DDF-8AEE-1591635DDBB9Q41819420-F0DD4A10-BDCD-486C-8581-936C7EBF20F1Q43228739-994BF990-DE6D-4739-A52A-400E993438C5Q44494542-59F439DD-40CE-4189-98AC-14361399CD63Q46622457-97876FE7-9B60-4BDF-8079-5FCE8888908FQ47100160-05A65B3D-BA20-49AA-811A-8EBAD14805ACQ47117550-17A2ED28-8965-43D4-83AD-C6E18340FAADQ48497390-51EC65D7-43F8-4254-8C73-B9499AB0D220Q49925719-6FDFBC5C-41D0-4276-ADC9-2CDAD61DCCA8Q51353755-5E3982A0-5F48-43E4-876F-BC7070729499Q57471361-1A1F4810-FAF7-4AD0-8009-F9A67E626FC2
P2860
Pharmacokinetics of an immediate-release oral formulation of Fampridine (4-aminopyridine) in normal subjects and patients with spinal cord injury.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Pharmacokinetics of an immedia ...... ients with spinal cord injury.
@en
Pharmacokinetics of an immediate-release oral formulation of Fampridine
@nl
type
label
Pharmacokinetics of an immedia ...... ients with spinal cord injury.
@en
Pharmacokinetics of an immediate-release oral formulation of Fampridine
@nl
prefLabel
Pharmacokinetics of an immedia ...... ients with spinal cord injury.
@en
Pharmacokinetics of an immediate-release oral formulation of Fampridine
@nl
P2093
P2860
P356
P1476
Pharmacokinetics of an immedia ...... ients with spinal cord injury.
@en
P2093
P2860
P304
P356
10.1177/0091270003251388
P577
2003-04-01T00:00:00Z